Investment Summary

Eagle Pharmaceuticals Invests In Enalare Therapeutics

On August 9, 2022, Eagle Pharmaceuticals invested in life science company Enalare Therapeutics

Investment Highlights
  • This is Eagle Pharmaceuticals’ 3rd transaction in the Life Science sector.
  • This is Eagle Pharmaceuticals’ 2nd transaction in the United States.
  • This is Eagle Pharmaceuticals’ 1st transaction in New Jersey.

Investment Summary
Date 2022-08-09
Target Enalare Therapeutics
Sector Life Science
Investor(s) Eagle Pharmaceuticals
Deal Type Stake Purchase

Target

Enalare Therapeutics

Princeton, New Jersey, United States
Enalare Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including community drug overdose, postoperative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, New Jersey.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Eagle Pharmaceuticals

Woodcliff Lake, New Jersey, United States
Category Company
Founded 2007
Sector Life Science
Employees134
Revenue 317M USD (2022)
DESCRIPTION

Eagle Pharmaceuticals is a pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle Pharmaceuticals was founded in 2007 and is based in Woodcliff Lake, New Jersey.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 3 of 3
Type (Stake Purchase) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 2 of 2
Year (2022) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-28 Acacia Pharma

Cambridge, United Kingdom

Acacia Pharma is a pharmaceutical company specializing in the development of drugs for cancer supportive care. The growth in the cancer supportive care market has been driven by the increasing incidence of cancer, the expansion of effective cancer therapies and the desire to improve both the effectiveness of treatment and the quality of life of cancer patients. Acacia Pharma was founded in 2007 and is based in Cambridge, United Kingdom.

Buy $95M
Mergr

Product

Company

Legal